Drug intelligence / Profile preview

LLE-aCD135

Development stage: Preclinical
Lead developer: University Children's Hospital Tübingen
Modality: Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

**LLE-aCD135** is an experimental linker-label epitope tagged anti-CD135 antibody adapter molecule developed for use with the Adapter CAR T-cell platform. The antibody component binds CD135, also known as Fms-related receptor tyrosine kinase 3, on acute myeloid leukemia cells, while its biotin-containing linker-label epitope is recognized by AdCAR T cells. This bridges AdCAR T cells to CD135-positive target cells and enables controlled T-cell activation and cytotoxicity. It has been evaluated in preclinical acute myeloid leukemia models, including mouse patient-derived xenograft studies, rather than as a standalone clinical medicine.

Other names: LLE-aCD135LLE-aCD-135LLE-aCD 135LLE-tagged anti-CD135 antibody

Targets

FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on LLE-aCD135.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LLE-aCD135.

Explore the full profile